STATROL by Alcon is clinical pharmacology the anti-infective components in statrol ophthalmic ointment provide action against specific organisms susceptible to them. Approved for the topical treatment of infections of the external eye, its adnexa caused by susceptible bacteria. First approved in 1974.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
STATROL is a topical ophthalmic ointment combining polymyxin B sulfate and neomycin sulfate for treatment of external eye infections caused by susceptible bacteria. It provides broad-spectrum coverage against gram-negative organisms including Pseudomonas aeruginosa and Staphylococcus aureus, but lacks activity against streptococci and serratia. This is a legacy small-molecule antibiotic product approved nearly 50 years ago.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect headcount rationalization and transition focus toward generic supply chain or brand transition strategies.
CLINICAL PHARMACOLOGY The anti-infective components in STATROL Ophthalmic Ointment provide action against specific organisms susceptible to them. Polymyxin B Sulfate and Neomycin Sulfate are active in vitro against Staphylococcus aureus, Escherichia coli, Klebsiella/Enterobacter species, Neisseria…
Worked on STATROL at Alcon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on STATROL presents limited growth opportunities given LOE approaching status and zero linked job postings; career value lies in defensive brand management, generic transition strategy, and operational efficiency. This is a consolidation/optimization role rather than a growth platform.